Stem-Cell Therapy for Type 1 Diabetes Reduced Patient's Insulin Needs by 91%
Vertex Moves Full Steam Ahead on Type 1 Diabetes Drug Trial With FDA's OK | BioSpace
Vertex to Acquire ViaCyte for $320M, Growing Diabetes Cell Therapy Pipeline
Clinical Trial for Novel Investigational Treatment of Type 1 Diabetes Open for Enrollment in Miami - World Stem Cell Summit
Vertex buys ViaCyte for $320M, clearing out T1D competition
Vertex präsentiert neue Daten aus der klinischen Phase-1/2-Studie zu VX-880 bei den 82. Scientific Sessions der American Diabetes Association | Business Wire
Vertex spends nearly $1bn on Semma's unproven diabetes cell tech | Evaluate
Can Vertex Pharmaceuticals and Douglas Melton CURE Type 1 Diabetes? | VX880 - YouTube
Vertex Acquires Semma Therapeutics Diabetes Research Firm
Vertex stock falls after FDA halts diabetes study in surprise move - The Boston Globe
Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes - PMLiVE
Frontiers | Stem Cell-Based Clinical Trials for Diabetes Mellitus
FDA orders stop to Vertex diabetes study - Boston Business Journal
Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte
Vertex reports positive results for first patient in Type 1 diabetes trial - The Boston Globe
Vertex: Trial of New Type 1 Diabetes Cell Therapy Put on Hold - DSM
Vertex Type 1 Diabetes Research Stirs Hope for Stem Cell-Based 'Cure'
Vertex: New Stem Cell Based Type 1 Diabetes Treatment Shown Effective in First Patient - DSM
Vertex: FDA pausiert Diabetes-Studie – Aktie unter Druck - DER AKTIONÄR
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff
JDRF Report: Vertex Has a New Horizon: Curing Type 1 Diabetes
Vertex to buy Semma Therapeutics for $950m in cash
Vertex (VRTX) Stock Falls After FDA Pauses Diabetes Study in Surprise Move - Bloomberg
Vertex to acquire rival diabetes drug developer ViaCyte
